#USA #San Francisco #Prostate Cancer #Verana Health #AQUA Registry

Verana Health Introduces the World's Largest Dataset for Prostate Cancer

In a landmark initiative, Verana Health®, a pioneering digital health company, has launched what is being hailed as the largest curated real-world dataset specifically for prostate cancer. This ambitious project is set to transform the landscape of clinical research and patient care by providing researchers with comprehensive longitudinal insights into various aspects of the disease, from detection to treatment and patient outcomes.

Prostate cancer stands as the most prevalent cancer diagnosis among men in the United States, with statistics revealing that approximately one in nine men will be diagnosed with this condition at some stage in their lives. In light of its significance, Verana Health's announcement is particularly timely, coinciding with the Annual Meeting of the American Urological Association (AUA), which is the largest congregation of urologists and urologic healthcare professionals globally. This event, taking place in Washington, DC, from May 15 to 18, serves as a platform to explore cutting-edge research, updated clinical guidelines, and technological advancements within the field.

As part of this groundbreaking development, Verana Health has focused on its role as the exclusive data and analytics partner of the AUA Quality (AQUA)® Registry. Through an innovative curation process that employs artificial intelligence (AI) and large language model (LLM) techniques, the company transforms unstructured electronic health record (EHR) data into research-ready datasets of the highest quality.

The newly unveiled prostate cancer dataset encompasses data contributed by urologists associated with the AQUA Registry and is further enhanced by the recent merger with COTA, significantly extending access to a vast network of more than 30 Academic Medical Centers and 10 million oncology patients. The dataset aggregates structured and unstructured EHR data from over 430,000 patients, harnessing proprietary AI modeling to meticulously extract, validate, and harmonize crucial clinical information.

This comprehensive dataset includes essential variables such as the Gleason Score, TNM Stage, and PSA levels—factors that are critical in determining the aggressiveness, spread, and treatment options for prostate cancer. The inclusion of castration status is also notable, as it plays a pivotal role in the management of this disease.

The implications of this real-world data (RWD) analysis are profound. Researchers can identify patients with localized cancer and examine treatment patterns and outcomes. They can also assess whether patients are receiving treatments aligned with AUA recommendations based on the severity of their condition. Additionally, tracking patient responses to therapies becomes more streamlined with this wealth of data.

The potential for real-world evidence (RWE), drawn from RWD, is significant, particularly in enhancing prostate cancer research and improving patient care. Key areas where RWE can make an impact include:

• - Early Detection and Intervention: RWD analysis can identify urinary biomarkers and pathology indicators that facilitate earlier disease detection and better risk stratification, ultimately aiding in reducing mortality through timely intervention.
• - Validation of Treatment Paths: By analyzing data trends, researchers can confirm the appropriateness and effectiveness of treatment plans and active surveillance strategies.
• - Accelerating Clinical Trials: RWE offers valuable insights that boost the efficiency and effectiveness of prostate cancer trials by pinpointing urology practices that treat patients fitting specific early-stage cancer profiles.

Sujay Jadhav, the CEO of Verana Health, expressed enthusiasm for the new dataset, stating, "The AQUA Registry has long been regarded in the industry as the gold standard for urological research. We're excited to provide this essential dataset to support the life sciences community in driving focus on early detection, prompt treatment, and accelerated research for improved outcomes."

Dr. Jennifer Bepple, board-certified urologist and clinical advisor at Verana Health, highlighted the critical role of RWD in bridging gaps left by clinical trials, evaluating long-term treatment effectiveness across diverse patient populations, and monitoring safety in routine practice.

For researchers seeking further information, Verana Health invites interested parties to engage during the AUA 2026 Annual Meeting at Booth 2469 or post-event. A webinar titled 'Beyond Prostate Cancer Diagnosis—Understanding the Patient Journey' is also scheduled for May 26, providing an in-depth exploration of the subject matter.

About Verana Health

Verana Health, Inc.® is at the forefront of revolutionizing patient care and clinical research by leveraging physician expertise and artificial intelligence to unlock the potential of real-world data. With exclusive access to the world's largest patient data sources across various areas including oncology, ophthalmology, neurology, and urology, Verana Health is committed to producing meaningful real-world evidence that informs better patient care and accelerates the development of new therapies. For more details, visit www.veranahealth.com.